Anumana Receives U.S. FDA 510(k) Clearance for ECG-AI Algorithm to Detect Low Ejection Fraction
Anumana, Inc. , a leading AI-driven health technology and nference portfolio company working in collaboration with Mayo Clinic , today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for ECG-AI LEF, a breakthrough artificial intelligence (AI)-powered medical device to detect low ejection fraction (LEF) in patients at risk of heart failure.
- Anumana, Inc. , a leading AI-driven health technology and nference portfolio company working in collaboration with Mayo Clinic , today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for ECG-AI LEF, a breakthrough artificial intelligence (AI)-powered medical device to detect low ejection fraction (LEF) in patients at risk of heart failure.
- View the full release here: https://www.businesswire.com/news/home/20231002851453/en/
Screen shot of sample data from Anumana's ECG-AI LEF, a breakthrough artificial intelligence (AI)-powered medical device to detect low ejection fraction (LEF) in patients at risk of heart failure. - Anumana spearheaded the effort to bring reimbursement to ECG-AI, receiving approval for two Category III CPT® codes from the American Medical Association in 2022.
- To learn more about ECG-AI LEF and schedule a demo, visit us at anumana.ai .